25 XP   0   0   10

Formycon AG
Buy, Hold or Sell?

Let's analyse Formycon together

PenkeI guess you are interested in Formycon AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Formycon AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Formycon AG

I send you an email if I find something interesting about Formycon AG.

Quick analysis of Formycon (30 sec.)










What can you expect buying and holding a share of Formycon? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€24.21
Expected worth in 1 year
€26.38
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€2.17
Return On Investment
5.4%

For what price can you sell your share?

Current Price per Share
€39.95
Expected price per share
€0 - €47.50
How sure are you?
50%

1. Valuation of Formycon (5 min.)




Live pricePrice per Share (EOD)

€39.95

Intrinsic Value Per Share

€-71.03 - €-20.23

Total Value Per Share

€-46.82 - €3.97

2. Growth of Formycon (5 min.)




Is Formycon growing?

Current yearPrevious yearGrowGrow %
How rich?$457.2m$152.3m$254.4m62.5%

How much money is Formycon making?

Current yearPrevious yearGrowGrow %
Making money-$14.7m$30.7m-$45.5m-308.8%
Net Profit Margin-57.7%108.4%--

How much money comes from the company's main activities?

3. Financial Health of Formycon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#113 / 1010

Most Revenue
#157 / 1010

Most Profit
#55 / 1010

Most Efficient
#26 / 1010

What can you expect buying and holding a share of Formycon? (5 min.)

Welcome investor! Formycon's management wants to use your money to grow the business. In return you get a share of Formycon.

What can you expect buying and holding a share of Formycon?

First you should know what it really means to hold a share of Formycon. And how you can make/lose money.

Speculation

The Price per Share of Formycon is €39.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Formycon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Formycon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €24.21. Based on the TTM, the Book Value Change Per Share is €0.54 per quarter. Based on the YOY, the Book Value Change Per Share is €4.81 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Formycon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.050.1%0.050.1%1.162.9%0.190.5%0.090.2%
Usd Book Value Change Per Share4.2910.7%0.581.5%5.1512.9%1.263.1%0.651.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.2910.7%0.581.5%5.1512.9%1.263.1%0.651.6%
Usd Price Per Share66.55-76.85-65.88-50.43-36.10-
Price to Earnings Ratio304.40-351.54--68.64--102.19-29.90-
Price-to-Total Gains Ratio15.50--10.39--188.27-18,222,861.74--2,392,409.93-
Price to Book Ratio2.57-3.39-14.03-11.46-14.34-
Price-to-Total Gains Ratio15.50--10.39--188.27-18,222,861.74--2,392,409.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share42.742505
Number of shares23
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.581.26
Usd Total Gains Per Share0.581.26
Gains per Quarter (23 shares)13.3528.92
Gains per Year (23 shares)53.41115.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1053430116106
20107960231222
301601490347338
402142020463454
502672550578570
603203080694686
703743610810802
804274140925918
90481467010411034
100534520011571150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.00.00.0100.0%5.06.00.045.5%5.014.00.026.3%17.022.00.043.6%17.037.00.031.5%
Book Value Change Per Share1.01.01.033.3%3.03.05.027.3%6.06.07.031.6%13.017.09.033.3%16.018.020.029.6%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.054.00.0%
Total Gains per Share1.01.01.033.3%3.03.05.027.3%6.06.07.031.6%13.017.09.033.3%16.018.020.029.6%

Fundamentals of Formycon

About Formycon AG

Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Fundamental data was last updated by Penke on 2024-04-10 04:45:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Formycon AG.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Formycon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • A Net Profit Margin of 4.1% means that €0.04 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Formycon AG:

  • The MRQ is 4.1%. The company is making a profit. +1
  • The TTM is -57.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ4.1%TTM-57.7%+61.8%
TTM-57.7%YOY108.4%-166.1%
TTM-57.7%5Y7.7%-65.4%
5Y7.7%10Y-68.3%+76.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%-207.2%+211.3%
TTM-57.7%-216.8%+159.1%
YOY108.4%-282.3%+390.7%
5Y7.7%-436.8%+444.5%
10Y-68.3%-597.3%+529.0%
1.1.2. Return on Assets

Shows how efficient Formycon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • 0.2% Return on Assets means that Formycon generated €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Formycon AG:

  • The MRQ is 0.2%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -1.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.2%TTM-1.6%+1.8%
TTM-1.6%YOY15.7%-17.3%
TTM-1.6%5Y0.7%-2.3%
5Y0.7%10Y-0.1%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2%-13.3%+13.5%
TTM-1.6%-12.8%+11.2%
YOY15.7%-11.6%+27.3%
5Y0.7%-13.8%+14.5%
10Y-0.1%-15.6%+15.5%
1.1.3. Return on Equity

Shows how efficient Formycon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • 0.4% Return on Equity means Formycon generated €0.00 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Formycon AG:

  • The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -3.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-3.9%+4.3%
TTM-3.9%YOY20.7%-24.6%
TTM-3.9%5Y1.1%-5.0%
5Y1.1%10Y0.0%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4%-16.9%+17.3%
TTM-3.9%-16.1%+12.2%
YOY20.7%-14.9%+35.6%
5Y1.1%-19.3%+20.4%
10Y0.0%-20.1%+20.1%

1.2. Operating Efficiency of Formycon AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Formycon is operating .

  • Measures how much profit Formycon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • An Operating Margin of 14.8% means the company generated €0.15  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Formycon AG:

  • The MRQ is 14.8%. The company is operating less efficient.
  • The TTM is -7.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ14.8%TTM-7.6%+22.4%
TTM-7.6%YOY-23.6%+15.9%
TTM-7.6%5Y-9.7%+2.1%
5Y-9.7%10Y-76.8%+67.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.8%-298.0%+312.8%
TTM-7.6%-238.5%+230.9%
YOY-23.6%-288.4%+264.8%
5Y-9.7%-486.2%+476.5%
10Y-76.8%-628.4%+551.6%
1.2.2. Operating Ratio

Measures how efficient Formycon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.85 means that the operating costs are €0.85 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Formycon AG:

  • The MRQ is 0.852. The company is less efficient in keeping operating costs low.
  • The TTM is 0.743. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.852TTM0.743+0.109
TTM0.743YOY0.736+0.007
TTM0.7435Y0.662+0.081
5Y0.66210Y1.122-0.460
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8523.235-2.383
TTM0.7433.310-2.567
YOY0.7363.838-3.102
5Y0.6625.679-5.017
10Y1.1227.823-6.701

1.3. Liquidity of Formycon AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Formycon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.02 means the company has €1.02 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Formycon AG:

  • The MRQ is 1.016. The company is just able to pay all its short-term debts.
  • The TTM is 0.878. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.016TTM0.878+0.138
TTM0.878YOY3.716-2.838
TTM0.8785Y5.576-4.698
5Y5.57610Y8.227-2.650
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0163.863-2.847
TTM0.8784.169-3.291
YOY3.7165.337-1.621
5Y5.5766.122-0.546
10Y8.2276.434+1.793
1.3.2. Quick Ratio

Measures if Formycon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • A Quick Ratio of 0.93 means the company can pay off €0.93 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Formycon AG:

  • The MRQ is 0.926. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.634. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.926TTM0.634+0.292
TTM0.634YOY2.438-1.804
TTM0.6345Y3.332-2.698
5Y3.33210Y9.945-6.613
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9263.504-2.578
TTM0.6343.991-3.357
YOY2.4385.371-2.933
5Y3.3326.088-2.756
10Y9.9456.395+3.550

1.4. Solvency of Formycon AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Formycon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Formycon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.53 means that Formycon assets are financed with 53.2% credit (debt) and the remaining percentage (100% - 53.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Formycon AG:

  • The MRQ is 0.532. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.565. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.532TTM0.565-0.034
TTM0.565YOY0.249+0.316
TTM0.5655Y0.212+0.354
5Y0.21210Y0.194+0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5320.339+0.193
TTM0.5650.337+0.228
YOY0.2490.271-0.022
5Y0.2120.368-0.156
10Y0.1940.388-0.194
1.4.2. Debt to Equity Ratio

Measures if Formycon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Formycon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 113.6% means that company has €1.14 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Formycon AG:

  • The MRQ is 1.136. The company is able to pay all its debts with equity. +1
  • The TTM is 1.308. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.136TTM1.308-0.172
TTM1.308YOY0.410+0.898
TTM1.3085Y0.373+0.936
5Y0.37310Y0.298+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1360.392+0.744
TTM1.3080.403+0.905
YOY0.4100.335+0.075
5Y0.3730.427-0.054
10Y0.2980.461-0.163

2. Market Valuation of Formycon AG

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Formycon generates.

  • Above 15 is considered overpriced but always compare Formycon to the Biotechnology industry mean.
  • A PE ratio of 304.40 means the investor is paying €304.40 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Formycon AG:

  • The EOD is 195.508. Based on the earnings, the company is expensive. -2
  • The MRQ is 304.396. Based on the earnings, the company is expensive. -2
  • The TTM is 351.539. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD195.508MRQ304.396-108.887
MRQ304.396TTM351.539-47.144
TTM351.539YOY-68.635+420.175
TTM351.5395Y-102.193+453.732
5Y-102.19310Y29.900-132.093
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD195.508-2.300+197.808
MRQ304.396-2.656+307.052
TTM351.539-2.718+354.257
YOY-68.635-4.145-64.490
5Y-102.193-6.258-95.935
10Y29.900-6.315+36.215
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Formycon AG:

  • The EOD is -8.535. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.289. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -31.162. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.535MRQ-13.289+4.754
MRQ-13.289TTM-31.162+17.873
TTM-31.162YOY-45.383+14.221
TTM-31.1625Y6,140.114-6,171.276
5Y6,140.11410Y2,708.072+3,432.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.535-2.974-5.561
MRQ-13.289-3.306-9.983
TTM-31.162-3.508-27.654
YOY-45.383-5.613-39.770
5Y6,140.114-8.378+6,148.492
10Y2,708.072-8.873+2,716.945
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Formycon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.57 means the investor is paying €2.57 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Formycon AG:

  • The EOD is 1.650. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.570. Based on the equity, the company is underpriced. +1
  • The TTM is 3.387. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.650MRQ2.570-0.919
MRQ2.570TTM3.387-0.817
TTM3.387YOY14.033-10.646
TTM3.3875Y11.462-8.075
5Y11.46210Y14.341-2.879
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6501.914-0.264
MRQ2.5702.116+0.454
TTM3.3872.097+1.290
YOY14.0332.881+11.152
5Y11.4623.550+7.912
10Y14.3413.936+10.405
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Formycon AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.0120.543+639%4.812-17%1.175+241%0.608+560%
Book Value Per Share--24.20721.532+12%8.065+200%6.889+251%3.967+510%
Current Ratio--1.0160.878+16%3.716-73%5.576-82%8.227-88%
Debt To Asset Ratio--0.5320.565-6%0.249+113%0.212+151%0.194+175%
Debt To Equity Ratio--1.1361.308-13%0.410+177%0.373+205%0.298+282%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0510.0510%1.086-95%0.180-72%0.087-41%
Free Cash Flow Per Share---1.170-1.098-6%-0.397-66%-0.261-78%-0.139-88%
Free Cash Flow To Equity Per Share--1.5320.844+82%-0.184+112%0.209+632%0.185+726%
Gross Profit Margin--0.7580.922-18%1.026-26%0.993-24%0.997-24%
Intrinsic Value_10Y_max---20.233--------
Intrinsic Value_10Y_min---71.031--------
Intrinsic Value_1Y_max---0.771--------
Intrinsic Value_1Y_min---2.902--------
Intrinsic Value_3Y_max---3.273--------
Intrinsic Value_3Y_min---12.423--------
Intrinsic Value_5Y_max---6.931--------
Intrinsic Value_5Y_min---25.929--------
Market Cap705393155.000-56%1098259180.0001268353983.333-13%1087223617.500+1%832336972.895+32%595812169.895+84%
Net Profit Margin--0.041-0.577+1500%1.084-96%0.077-46%-0.683+1759%
Operating Margin--0.148-0.076+152%-0.236+259%-0.097+166%-0.768+618%
Operating Ratio--0.8520.743+15%0.736+16%0.662+29%1.122-24%
Pb Ratio1.650-56%2.5703.387-24%14.033-82%11.462-78%14.341-82%
Pe Ratio195.508-56%304.396351.539-13%-68.635+123%-102.193+134%29.900+918%
Price Per Share39.950-56%62.20071.833-13%61.575+1%47.139+32%33.744+84%
Price To Free Cash Flow Ratio-8.535+36%-13.289-31.162+134%-45.383+242%6140.114-100%2708.072-100%
Price To Total Gains Ratio9.958-56%15.504-10.389+167%-188.269+1314%18222861.744-100%-2392409.928+15430770%
Quick Ratio--0.9260.634+46%2.438-62%3.332-72%9.945-91%
Return On Assets--0.002-0.016+919%0.157-99%0.007-73%-0.001+131%
Return On Equity--0.004-0.039+1022%0.207-98%0.011-61%0.000+757%
Total Gains Per Share--4.0120.543+639%4.812-17%1.175+241%0.608+560%
Usd Book Value--457292378.400406767420.800+12%152360981.825+200%130137415.726+251%74935737.463+510%
Usd Book Value Change Per Share--4.2920.580+639%5.148-17%1.257+241%0.650+560%
Usd Book Value Per Share--25.89923.037+12%8.629+200%7.370+251%4.244+510%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0550.0550%1.162-95%0.193-72%0.093-41%
Usd Free Cash Flow---22105203.900-20746787.533-6%-7507488.300-66%-4925963.699-78%-2629071.323-88%
Usd Free Cash Flow Per Share---1.252-1.175-6%-0.425-66%-0.279-78%-0.149-88%
Usd Free Cash Flow To Equity Per Share--1.6390.903+82%-0.197+112%0.224+632%0.198+726%
Usd Market Cap754700136.535-56%1175027496.6821357011926.768-13%1163220548.363+1%890517327.300+32%637459440.571+84%
Usd Price Per Share42.743-56%66.54876.854-13%65.879+1%50.435+32%36.103+84%
Usd Profit--1930099.600-14740725.567+864%30783029.063-94%2541711.496-24%1233136.289+57%
Usd Revenue--46849851.10024480025.267+91%9174392.233+411%12079442.354+288%9014025.614+420%
Usd Total Gains Per Share--4.2920.580+639%5.148-17%1.257+241%0.650+560%
 EOD+3 -5MRQTTM+23 -9YOY+12 -225Y+16 -1810Y+22 -12

3.2. Fundamental Score

Let's check the fundamental score of Formycon AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15195.508
Price to Book Ratio (EOD)Between0-11.650
Net Profit Margin (MRQ)Greater than00.041
Operating Margin (MRQ)Greater than00.148
Quick Ratio (MRQ)Greater than10.926
Current Ratio (MRQ)Greater than11.016
Debt to Asset Ratio (MRQ)Less than10.532
Debt to Equity Ratio (MRQ)Less than11.136
Return on Equity (MRQ)Greater than0.150.004
Return on Assets (MRQ)Greater than0.050.002
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Formycon AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.793
Ma 20Greater thanMa 5043.148
Ma 50Greater thanMa 10046.550
Ma 100Greater thanMa 20049.759
OpenGreater thanClose39.700
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in EUR. All numbers in thousands.

Summary
Total Assets912,944
Total Liabilities485,528
Total Stockholder Equity427,416
 As reported
Total Liabilities 485,528
Total Stockholder Equity+ 427,416
Total Assets = 912,944

Assets

Total Assets912,944
Total Current Assets83,395
Long-term Assets829,549
Total Current Assets
Cash And Cash Equivalents 36,865
Net Receivables 39,157
Inventory 965
Other Current Assets 6,408
Total Current Assets  (as reported)83,395
Total Current Assets  (calculated)83,395
+/-0
Long-term Assets
Property Plant Equipment 11,661
Goodwill 44,534
Intangible Assets 545,194
Other Assets 92,450
Long-term Assets  (as reported)829,549
Long-term Assets  (calculated)693,839
+/- 135,710

Liabilities & Shareholders' Equity

Total Current Liabilities82,086
Long-term Liabilities403,442
Total Stockholder Equity427,416
Total Current Liabilities
Short-term Debt 1,086
Accounts payable 19,721
Other Current Liabilities 59,943
Total Current Liabilities  (as reported)82,086
Total Current Liabilities  (calculated)80,750
+/- 1,336
Long-term Liabilities
Long term Debt Total 7,722
Other Liabilities 395,720
Long-term Liabilities  (as reported)403,442
Long-term Liabilities  (calculated)403,442
+/-0
Total Stockholder Equity
Common Stock16,039
Retained Earnings -163
Other Stockholders Equity 411,540
Total Stockholder Equity (as reported)427,416
Total Stockholder Equity (calculated)427,416
+/-0
Other
Cash And Equivalents36,865
Cash and Short Term Investments 36,865
Common Stock Shares Outstanding 15,955
Current Deferred Revenue1,336
Liabilities and Stockholders Equity 912,944
Net Debt -28,057
Net Tangible Assets -117,778
Net Working Capital 1,309
Short Long Term Debt Total 8,808



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-06-302023-03-312022-12-312022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-31
> Total Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
7,889
7,889
0
7,640
0
11,652
0
15,445
22,618
22,618
16,906
16,906
28,687
28,687
27,147
27,147
25,428
25,428
25,186
25,186
21,253
21,253
30,828
30,828
42,204
42,204
39,624
39,624
54,009
54,009
0
53,555
0
52,180
0
75,598
0
70,944
0
66,333
0
823,643
853,697
0
912,944
912,9440853,697823,643066,333070,944075,598052,180053,555054,00954,00939,62439,62442,20442,20430,82830,82821,25321,25325,18625,18625,42825,42827,14727,14728,68728,68716,90616,90622,61822,61815,445011,65207,64007,8897,8890000000000000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,621
0
2,077
0
6,603
0
10,902
0
0
0
12,876
0
24,826
0
23,407
0
21,544
20,672
20,787
16,841
16,964
26,631
26,714
21,838
21,932
18,746
18,891
28,257
28,533
28,060
28,180
26,679
26,929
50,507
50,645
44,071
44,501
37,992
37,992
43,364
43,364
30,502
83,395
83,395
83,39583,39530,50243,36443,36437,99237,99244,50144,07150,64550,50726,92926,67928,18028,06028,53328,25718,89118,74621,93221,83826,71426,63116,96416,84120,78720,67221,544023,407024,826012,87600010,90206,60302,07702,62100000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
379
0
213
0
4,632
0
899
0
0
0
289
0
4,722
0
622
0
5,814
2,995
2,995
3,444
3,444
4,505
4,505
4,842
4,842
7,336
7,336
7,489
7,489
0
22,116
0
19,999
0
42,009
0
33,473
0
25,029
0
18,243
9,820
0
36,865
36,86509,82018,243025,029033,473042,009019,999022,11607,4897,4897,3367,3364,8424,8424,5054,5053,4443,4442,9952,9955,814062204,722028900089904,6320213037900000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
0
2
0
0
0
9,506
0
0
0
8,962
0
15,835
0
19,675
0
11,975
10,972
10,972
10,973
10,973
10,974
10,974
6,973
6,973
4,972
4,972
473
473
0
238
0
235
0
238
0
153
0
150
0
150
0
0
0
0001500150015302380235023804734734,9724,9726,9736,97310,97410,97410,97310,97310,97210,97211,975019,675015,83508,9620009,506000201,80000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
277
277
0
0
0
0
0
0
1
1
3,252
3,252
3,963
3,963
2,757
2,757
2,951
2,951
5,209
5,209
1,332
1,332
10,519
10,519
8,418
8,418
5,168
5,168
7,559
7,559
4,920
4,920
5,865
5,865
6,894
7,273
9,496
9,926
7,747
7,747
22,066
22,066
15,475
39,157
39,157
39,15739,15715,47522,06622,0667,7477,7479,9269,4967,2736,8945,8655,8654,9204,9207,5597,5595,1685,1688,4188,41810,51910,5191,3321,3325,2095,2092,9512,9512,7572,7573,9633,9633,2523,252110000002772770000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
55
392
0
1,780
0
1,886
0
222
88
88
27
3,279
13
3,975
21
2,878
427
3,495
864
6,572
775
2,311
56
10,658
28
8,722
54
5,367
12,282
20,117
379
5,455
147
6,262
130
130
83
83
3,211
3,211
150
2,903
4,636
6,408
6,408
6,4086,4084,6362,9031503,2113,21183831301306,2621475,45537920,11712,2825,367548,7222810,658562,3117756,5728643,4954272,878213,975133,27927888822201,88601,7800392550000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,268
0
5,562
0
5,049
0
4,543
0
0
0
4,030
0
3,861
0
3,740
0
3,884
0
4,399
0
4,289
0
4,114
0
20,272
0
20,733
0
25,475
0
25,376
0
25,251
0
24,953
0
26,442
0
28,341
0
780,279
823,195
0
829,549
829,5490823,195780,279028,341026,442024,953025,251025,376025,475020,733020,27204,11404,28904,39903,88403,74003,86104,0300004,54305,04905,56205,26800000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,536
3,536
0
3,745
0
3,343
0
2,987
2,560
2,560
2,689
2,689
2,620
2,620
2,553
2,606
2,660
2,788
3,049
3,409
3,398
3,398
3,255
3,255
3,521
3,521
3,473
3,473
3,567
3,567
3,701
3,701
3,670
3,682
3,501
3,501
3,695
3,695
3,283
3,343
11,947
11,947
11,516
11,661
11,661
11,66111,66111,51611,94711,9473,3433,2833,6953,6953,5013,5013,6823,6703,7013,7013,5673,5673,4733,4733,5213,5213,2553,2553,3983,3983,4093,0492,7882,6602,6062,5532,6202,6202,6892,6892,5602,5602,98703,34303,74503,5363,5360000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,425
1,425
0
1,537
0
0
0
1,379
1,300
1,300
1,222
1,222
1,143
1,143
1,064
1,064
985
985
906
906
828
828
749
749
670
670
591
591
512
512
0
433
0
355
0
276
0
197
0
118
0
20,910
44,534
0
44,534
44,534044,53420,9100118019702760355043305125125915916706707497498288289069069859851,0641,0641,1431,1431,2221,2221,3001,3001,3790001,53701,4251,4250000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,973
15,973
15,973
15,973
20,673
20,673
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000020,67320,67315,97315,97315,97315,9730000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,662
1,662
0
256
0
1,681
0
177
1,449
1,449
1,342
120
1,234
91
1,134
70
1,096
111
990
83
890
63
858
109
108
108
176
176
203
203
0
198
0
171
0
223
0
521
0
789
0
484,602
532,973
0
545,194
545,1940532,973484,60207890521022301710198020320317617610810810985863890839901111,096701,134911,2341201,3421,4491,44917701,681025601,6621,6620000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,791
1,791
0
0
0
0
0
1,563
1,485
1,485
1,369
1,369
1,241
1,241
1,287
1,287
1,291
1,291
1,465
1,465
1,014
1,014
941
941
94
94
665
665
796
796
489
489
632
632
418
0
1,034
1
689
689
85,562
493,572
0
92,450
92,450
92,45092,4500493,57285,56268968911,034041863263248948979679666566594949419411,0141,0141,4651,4651,2911,2911,2871,2871,2411,2411,3691,3691,4851,4851,563000001,7911,7910000000000000
> Total Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,368
5,368
0
3,380
0
2,890
0
3,194
7,865
7,865
3,795
3,795
2,931
2,931
2,276
2,276
1,731
1,731
4,295
4,295
3,269
3,269
5,284
5,284
9,072
9,072
6,384
6,384
4,200
4,200
0
5,345
0
5,351
0
7,563
0
12,135
0
10,262
0
424,967
497,117
0
485,528
485,5280497,117424,967010,262012,13507,56305,35105,34504,2004,2006,3846,3849,0729,0725,2845,2843,2693,2694,2954,2951,7311,7312,2762,2762,9312,9313,7953,7957,8657,8653,19402,89003,38005,3685,3680000000000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,115
3,508
0
3,105
0
2,389
0
2,493
449
449
3,265
2,271
1,949
645
1,343
1,335
493
260
2,613
2,309
1,265
1,128
4,710
3,435
8,446
4,723
5,900
3,800
3,497
2,611
4,618
3,467
4,780
3,595
7,166
5,019
3,592
9,651
9,890
5,594
20,502
20,502
50,666
82,086
82,086
82,08682,08650,66620,50220,5025,5949,8909,6513,5925,0197,1663,5954,7803,4674,6182,6113,4973,8005,9004,7238,4463,4354,7101,1281,2652,3092,6132604931,3351,3436451,9492,2713,2654494492,49302,38903,10503,5083,1150000000000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,800
0
2
0
0
0
9,506
0
0
0
8,962
0
15,835
0
19,675
0
11,975
0
10,972
0
10,973
1
1
0
6,973
0
4,972
0
473
0
238
0
235
0
0
0
0
0
0
0
956
21,715
0
1,086
1,086021,71595600000002350238047304,97206,97301110,973010,972011,975019,675015,83508,9620009,506000201,80000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001100000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,115
3,115
0
3,105
0
2,389
0
2,493
52
52
2,271
2,271
645
645
649
649
260
260
2,309
2,309
797
1,128
1,767
1,767
4,723
4,723
2,731
2,731
1,663
1,663
2,212
2,212
2,921
2,921
4,484
4,484
321
8,321
4,734
4,734
9,636
9,636
11,318
19,721
19,721
19,72119,72111,3189,6369,6364,7344,7348,3213214,4844,4842,9212,9212,2122,2121,6631,6632,7312,7314,7234,7231,7671,7671,1287972,3092,3092602606496496456452,2712,27152522,49302,38903,10503,1153,1150000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
392
0
0
0
0
0
205
397
397
994
994
1,305
1,305
694
686
233
233
304
1,935
468
468
2,942
1,667
2,897
2,897
1,928
1,069
1,119
948
1,100
1,255
691
674
1,146
535
1,668
1,330
3,276
860
9,910
9,821
17,525
61,279
59,943
59,94361,27917,5259,8219,9108603,2761,3301,6685351,1466746911,2551,1009481,1191,0691,9282,8972,8971,6672,9424684681,9353042332336866941,3051,3059949943973972050000039200000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,861
0
275
0
501
0
701
0
0
0
1,525
0
2,286
0
941
0
1,471
0
1,986
0
2,142
0
1,849
0
4,348
0
2,584
0
1,588
0
1,878
0
1,756
0
2,545
0
2,484
0
4,668
0
404,465
446,451
0
403,442
403,4420446,451404,46504,66802,48402,54501,75601,87801,58802,58404,34801,84902,14201,98601,471094102,28601,5250007010501027501,86100000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,075
27,594
0
7,722
7,722027,59418,075000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
680
680
0
0
0
0
0
496
7,417
7,417
530
530
982
982
933
941
1,238
1,238
1,682
51
2,005
2,005
574
574
626
626
484
484
702
702
727
727
571
571
398
398
8,542
8,542
372
372
386,390
396,390
0
395,720
395,720
395,720395,7200396,390386,3903723728,5428,5423983985715717277277027024844846266265745742,0052,005511,6821,2381,2389419339829825305307,4177,417496000006806800000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
2,521
2,521
0
4,260
0
8,762
0
12,251
14,753
14,753
13,111
13,111
25,756
25,756
24,871
24,871
23,697
23,697
20,891
20,891
17,984
17,984
25,544
25,544
33,132
33,132
33,240
33,240
49,809
49,809
0
48,211
0
46,829
0
68,035
0
58,809
0
56,071
0
398,676
356,580
0
427,416
427,4160356,580398,676056,071058,809068,035046,829048,211049,80949,80933,24033,24033,13233,13225,54425,54417,98417,98420,89120,89123,69723,69724,87124,87125,75625,75613,11113,11114,75314,75312,25108,76204,26002,5212,5210000000000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
4,576
4,576
0
5,082
0
7,370
0
8,627
8,627
8,627
8,627
8,627
9,063
9,063
9,080
9,080
9,085
9,085
9,100
9,100
9,100
9,100
9,344
9,344
9,344
9,344
9,423
9,423
10,000
10,000
10,000
10,000
10,000
10,000
11,000
11,000
11,047
11,047
11,065
11,065
15,065
15,065
15,129
16,039
16,039
16,03916,03915,12915,06515,06511,06511,06511,04711,04711,00011,00010,00010,00010,00010,00010,00010,0009,4239,4239,3449,3449,3449,3449,1009,1009,1009,1009,0859,0859,0809,0809,0639,0638,6278,6278,6278,6278,62707,37005,08204,5764,5760000000000000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000-4,4410-4,1400-4,0120-3,7050-3,3950-3,2630-3,126000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,345
0
4,357
0
10,077
0
18,248
0
0
0
18,248
0
28,928
0
28,977
0
28,981
29,044
29,044
29,044
29,044
35,033
38,159
35,033
38,295
35,552
38,947
52,239
55,944
52,239
56,251
52,239
56,378
76,989
76,989
77,885
77,885
78,436
78,436
341,539
341,539
343,419
411,539
411,540
411,540411,539343,419341,539341,53978,43678,43677,88577,88576,98976,98956,37852,23956,25152,23955,94452,23938,94735,55238,29535,03338,15935,03329,04429,04429,04429,04428,981028,977028,928018,24800018,248010,07704,35703,34500000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue42,497
Cost of Revenue-30,425
Gross Profit12,07212,072
 
Operating Income (+$)
Gross Profit12,072
Operating Expense-29,800
Operating Income-17,728-17,728
 
Operating Expense (+$)
Research Development16,912
Selling General Administrative11,446
Selling And Marketing Expenses1,442
Operating Expense29,80029,800
 
Net Interest Income (+$)
Interest Income302
Interest Expense-143
Other Finance Cost-0
Net Interest Income159
 
Pretax Income (+$)
Operating Income-17,728
Net Interest Income159
Other Non-Operating Income Expenses0
Income Before Tax (EBT)49,528-84,984
EBIT - interestExpense = -17,871
36,596
36,135
Interest Expense143
Earnings Before Interest and Taxes (EBIT)-17,72849,671
Earnings Before Interest and Taxes (EBITDA)-15,866
 
After tax Income (+$)
Income Before Tax49,528
Tax Provision-604
Net Income From Continuing Ops35,99248,924
Net Income35,992
Net Income Applicable To Common Shares35,992
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses60,225
Total Other Income/Expenses Net67,256-159
 

Technical Analysis of Formycon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Formycon. The general trend of Formycon is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Formycon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Formycon AG.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 44.40 < 46.50 < 47.50.

The bearish price targets are: .

Tweet this
Formycon AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Formycon AG. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Formycon AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Formycon AG. The current macd is -2.15890467.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Formycon price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Formycon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Formycon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Formycon AG Daily Moving Average Convergence/Divergence (MACD) ChartFormycon AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Formycon AG. The current adx is 27.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Formycon shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Formycon AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Formycon AG. The current sar is 42.85.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Formycon AG Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Formycon AG. The current rsi is 33.79. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Formycon AG Daily Relative Strength Index (RSI) ChartFormycon AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Formycon AG. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Formycon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Formycon AG Daily Stochastic Oscillator ChartFormycon AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Formycon AG. The current cci is -76.65656128.

Formycon AG Daily Commodity Channel Index (CCI) ChartFormycon AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Formycon AG. The current cmo is -32.5901762.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Formycon AG Daily Chande Momentum Oscillator (CMO) ChartFormycon AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Formycon AG. The current willr is -76.64974619.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Formycon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Formycon AG Daily Williams %R ChartFormycon AG Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Formycon AG.

Formycon AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Formycon AG. The current atr is 1.56101156.

Formycon AG Daily Average True Range (ATR) ChartFormycon AG Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Formycon AG. The current obv is 201,162.

Formycon AG Daily On-Balance Volume (OBV) ChartFormycon AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Formycon AG. The current mfi is 28.17.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Formycon AG Daily Money Flow Index (MFI) ChartFormycon AG Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Formycon AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside

6.3. Candlestick Patterns

Formycon AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Formycon AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.793
Ma 20Greater thanMa 5043.148
Ma 50Greater thanMa 10046.550
Ma 100Greater thanMa 20049.759
OpenGreater thanClose39.700
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Formycon with someone you think should read this too:
  • Are you bullish or bearish on Formycon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Formycon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Formycon AG

I send you an email if I find something interesting about Formycon AG.


Comments

How you think about this?

Leave a comment

Stay informed about Formycon AG.

Receive notifications about Formycon AG in your mailbox!